Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently […]
THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating […]KRAS
Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer